Holmusk Raises USD 21.5 Million in Series A Round of Financing to Expand its US Operations

Holmusk was founded in 2015 and is headquartered in Singapore. The company has offices in New York City, London, and Shanghai. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and is part of the Innovations in Healthcare's 2020 Innovator Cohort

Fremont, CA: Data science and health technology company Holmusk secured USD 21.5 million in Series A funding round led by Optum Ventures and Health Catalyst Capital, with participation from existing investors Heritas Capital and other individuals. As part of the investment round, Dr Vijay Barathan from Optum Ventures and Charles Boorady from Health Catalyst Capital will be joining Holmusk’s Board of Directors soon. Proceeds from the investment round will allow Holmusk to expand its US operations in New York City and enable investment in its proprietary technology to harness and analyze real-world data to accelerate drug development and data-driven medicine.

"In situations like today, the need for Real-World Evidence is more pronounced than ever," said Nawal Roy, Holmusk's Founder & CEO. "We are fortunate to bring on partners like Optum Ventures and Health Catalyst Capital who understand the importance and are excited to join us in our mission to drive evidence-based care." Currently, the company is building the world's most massive Real-World Evidence (RWE) platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions.

Holmusk's revolutionary platform is made possible due to the combination of specialty behavioral health data and Holmusk's novel analytics platform. The new platform will deliver evidence-based insight that care providers, health care payers and patients can use to make fully informed care and treatment decisions, and better integrate care for people with both behavioral and chronic health needs. The same will also be helpful for pharmaceutical companies with R7D and commercialization of new drugs.

"Our team is encouraged by Holmusk's evidence-based approach to improving care for people suffering from behavioral health disorders, and we look forward to working closely with the Holmusk team to support the next phase of growth," said Dr Vijay Barathan of Optum Ventures.

Holmusk was founded in 2015 and is headquartered in Singapore. The company has offices in New York City, London, and Shanghai. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and is part of the Innovations in Healthcare's 2020 Innovator Cohort. "By redefining the EHR from a repository of data to a clinical decision support tool with connectivity to digital therapeutics, Holmusk is uniquely positioned to improve patient care while reducing administrative burden and supporting the research and development of new care models and therapies," said Charles Boorady of Health Catalyst Capital.